Datapoint: FDA Approves Generic Alternative to Symbicort

The FDA last week approved Mylan’s generic alternative to AstraZeneca’s Symbicort inhaler — the first on the market. The Mylan generic was approved to treat both asthma and COPD. For the treatment of asthma, Symbicort holds covered or better status for 89% of all insured lives under the pharmacy benefit. Among all covered lives, 53.4% have preferred access to Symbicort without utilization management restrictions.

SOURCE: MMIT Analytics, as of 3/21/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 18

Datapoint: CDPHP Selects New PBM

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 17

Datapoint: Oscar to Exit Two States

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today